Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Aarti Asnani , Randall T Peterson Added: 3 years ago
Survival rates among patients diagnosed with cancer have improved dramatically over the past few decades. In 2016, there were an estimated 16 million cancer survivors in the United States, a number expected to increase to 20 million over the subsequent decade.1 One-third of these patients will survive at least 5 years after their initial cancer diagnosis, largely due to cancer therapies that are… View more

Heart Failure

CV Disease in Special Populations
Cardiac Toxicity of Cancer Chemotherapy
Author(s): Aarti Asnani Start date: Aug 08, 2017

Heart Failure
Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
Author(s): Katelyn Storey , Scott W Sharkey Added: 3 years ago
During the past 25 years, takotsubo syndrome (TS) has emerged as an important form of acute myocardial injury characterized by a distinctive regional left ventricular (LV) contraction abnormality, often with marked reduction of the LV ejection fraction, and typically completely reversible. At presentation, TS is often indistinguishable from acute coronary syndrome, yet its occurrence is… View more

Heart Failure
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 week ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations
Cardio-oncology A-Z: Late Effects Cardiotoxicity
Author(s): Neha Bansal Added: 1 year ago
In this video we asked Dr Neha Bansal, Paediatric Cardiologist at Children’s Hospital at Montefiore to talk about the late effects of cardiotoxicity. Dr. Bansal’s research focuses are paediatric cardiomyopathy, pediatric cardiac transplants and paediatric cardio-oncology. Discussion Points 1. Late effects 2. How common late effects are 3. Risk factors that could predispose patients to late… View more

CV Disease in Special Populations
Aarti Asnani
Research Area(s) / Expertise: Job title: MD
Dr Asnani is Associate Director and an attending physician in the Cardio-Oncology Program at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts and is an active researcher in the field. She joined BIDMC in 2017 and prior to this worked at the Massachusetts General Hospital. She earned her medical degree at the Duke School of Medicine, Durham, North Carolina in 2008, one of the… View more
Alicia Okines
Research Area(s) / Expertise:

Cardio-oncology

 Job title: Consultant Medical Oncologist, Royal Marsden Hospital, London, UK
Dr Alicia Okines is a consultant in medical oncology at the Royal Marsden NHS Foundation Trust and the team leader for the Breast Cancer Systemic Therapy Trials team.Dr Okines studied pharmacology at the University of Sheffield, where she also pursued her medical training. Throughout her oncology residency at The Royal Marsden Hospital and the Institute of Cancer Research, she earned an MD(Res),… View more
A Case of Primary Cardiac B-cell Lymphoma Diagnosed with Cardiac MRI
Author(s): Kevin Lee , Iva Minga , Eryn Cameron , et al Added: 9 months ago

Imaging & Diagnostics

CV Disease in Special Populations